Rafael Holdings Inc (NYSE: RFL), a pharmaceutical company focused on developing novel cancer metabolism therapeutics, announced on Monday that it has appointed Ameet Mallik, Shannon Thyme Klinger and Mark McCamish, MD, PhD as its new directors.

Mallik is the chief executive officer of Rafael Holdings. He has more than 16 years of experience at Novartis, where he most recently served as executive vice president and head, US Oncology. He has served as the global head, Marketing, Value and Access and as head, Latin America and Canada for Novartis Oncology. He started his career at Novartis as head of Strategic Planning and has held various commercial leadership roles at Novartis and Sandoz. He was head of Biopharmaceuticals & Oncology Injectables at Sandoz.

Klinger is the chief legal officer for Moderna (NASDAQ GS: MRNA). She also serves on Moderna's executive committee and as corporate secretary. She served as chief legal officer and a member of the executive committee at Novartis. She had a ten-year tenure at Novartis, where she held other roles of increasing responsibility.

Mark McCamish, MD, PhD is president and chief executive officer at IconOVir Bio and earlier served as the president and chief executive officer of Forty Seven Inc. He is an international expert in biologic and biosimilars development and manufacturing and held senior executive roles at global pharmaceutical companies, including Abbott, Amgen and Novartis/Sandoz.